Takeda Aims for Mid-Teens Annual Growth in Japan Oncology Biz: Exec

Takafumi Horii, Head of Japan Oncology Business Unit, Takeda With a string of new cancer drugs and indications coming along in its pipeline, Takeda Pharmaceutical is targeting a compound annual growth rate in the mid-teens, or at least double-digit growth,...read more